REQUEST A DEMO
Total
USD $0.00
Search more companies

Sopharma AD (Bulgaria)

Main Activities: Medicinal and Botanical Manufacturing | Pharmaceutical Preparation Manufacturing
Full name: Sopharma AD Profile Updated: March 18, 2022
Buy our report for this company USD 29.95 Most recent financial data: 2021 Available in: English Download a sample report

Bulgarian drug maker Sopharma, which was established in 1933, is active in development, manufacturing and marketing of over 200 human pharmaceutical products.
The company produces mostly cardiovascular drugs, analgesics and vitamins and exports its output to more than 10 countries, with top destinations being Russia and other ex-Soviet states.
In July 2000, local company Elpharma set up by the engineering and trading firm Elektroimpex and Unifarm, a small local pharmaceuticals company, bought a 66.94% stake in Sopharma for USD 24 million. Elpharma also pledged to invest USD 7.5 million in Sopharma over the next three years. In mid-2003, Sopharma launched a consolidation of its subsidiaries in Bulgaria by merging with local drug maker Vramed.
The following year, the Sofia-based firm acquired control of local debt-ridden pharmaceuticals and rose oil producer Balgarska Rosa Sevtopolis.
In January 2006, U.S. Gramercy Emerging Market Fund bought a 7.57% stake of Sopharma from its majority owner for EUR 19.7 million. The U.S. investment fund gradually raised its stake in the drug maker to 17% by December 2006.
In December 2006, Sopharma bought for an undisclosed sum a 70% stake of local firm MineralCommers - the only manufacturer of amorphous silica in the Balkans.
In October 2007 Sopharma bought 108,500 shares, or less than 1.0 pct, from the IPO of Latvian peer Olainfarm in a bid to expand its presence on the Baltic market. The acquisition was part of the company’s plans to list on the Warsaw bourse by February 2008 and thus become the first Bulgarian firm to be listed on two stock exchanges. Also in October, Sopharma also bought 4.72% in Momina Krepost, raising its stake in the disposable medical supplies maker to 42.26%.
In November 2007, the blue-chip drug maker bought some 74% in Ukranian pharmaceutical producer Vitamini for an undisclosed sum.
In March 2008, Sopharma received approval from the Serbian anti-trust body to take control of Belgrade-based pharmaceutical firm Ivancic and Sons for an undisclosed sum.
In December 2009, Sopharma acquired a 51% stake in Latvian pharmaceutical wholesaler Briz at the amount of EUR 2.25 million.
The Sopharma group operates 14 pharmaceutical plants in Bulgaria, one in Ukraine and two in Serbia as of end-2012.

Headquarters
16 Iliensko shose Str.
Sofia; Sofia - city; Postal Code: 1220

Contact Details: Purchase the Sopharma AD report to view the information.

Website: http://www.sopharma.bg/

Basic Information
Total Employees:
Purchase the Sopharma AD report to view the information.
Outstanding Shares:
Purchase the Sopharma AD report to view the information.
Registered Capital:
Purchase the Sopharma AD report to view the information.
Financial Auditors:
Purchase the Sopharma AD report to view the information.
Ratings:
Purchase the Sopharma AD report to view the information.
Incorporation Date:
November 15, 1991
Key Executives
Purchase this report to view the information.
Executive Director and Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Ownership Details
Purchase this report to view the information.
27.86%
Purchase this report to view the information.
20.68%
Purchase this report to view the information.
9.68%
Purchase this report to view the information.
5.23%
Subsidiaries
Biopharm-Engineering AD
100%
Electroncommerce EOOD
100%
PAO Vitamini (Ukraine)
100%
Company Performance
Financial values in the chart are available after Sopharma AD report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency BGN. Absolute financial data is included in the purchased report.
Net sales revenue
11.41%
Total operating revenue
11.37%
Operating profit (EBIT)
37.34%
EBITDA
24.2%
Net Profit (Loss) for the Period
270.52%
Total assets
-2.81%
Total equity
16.63%
Operating Profit Margin (ROS)
0.64%
Net Profit Margin
4.06%
Return on Equity (ROE)
9.71%
Debt to Equity Ratio
-15.84%
Quick Ratio
0.15%
Cash Ratio
0.04%

Similar companies

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?